Pelthos Therapeutics Inc. (PTHS)
| Market Cap | 94.68M +31.2% |
| Revenue (ttm) | 43.30M |
| Net Income | -86.39M |
| EPS | -26.36 |
| Shares Out | 3.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,909 |
| Open | 24.61 |
| Previous Close | 25.00 |
| Day's Range | 24.00 - 25.84 |
| 52-Week Range | 18.19 - 37.50 |
| Beta | 3.13 |
| Analysts | Strong Buy |
| Price Target | 53.14 (+114.88%) |
| Earnings Date | Aug 13, 2026 |
About PTHS
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestati... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for PTHS stock is "Strong Buy." The 12-month stock price target is $53.14, which is an increase of 114.88% from the latest price.
News
Pelthos Therapeutics Proxy statement: Proxy filing
Pelthos Therapeutics filed a proxy statement on August 18, 2026, providing details for shareholder voting and corporate governance matters.
Pelthos Therapeutics Proxy statement: Proxy filing
Pelthos Therapeutics filed a proxy statement on August 18, 2026, providing details for shareholder voting and corporate governance matters.
Pelthos Therapeutics price target lowered to $45 from $75 at Alliance Global
Alliance Global lowered the firm’s price target on Pelthos Therapeutics (PTHS) to $45 from $75 and keeps a Buy rating on the shares after the company released their Q2 results…
Pelthos Therapeutics price target lowered to $64 from $66 at Oppenheimer
Oppenheimer analyst Jeff Jones lowered the firm’s price target on Pelthos Therapeutics (PTHS) to $64 from $66 and keeps an Outperform rating on the shares following quarterly results. The firm…
Pelthos Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth and prescription gains for ZELSUVMI, supported by expanded PBM access and new clinical guidelines. Net product revenue rose 45% sequentially, with improved adjusted EBITDA and a solid cash position. Upcoming launches of XEPI and XEGLYZE are on track, leveraging existing infrastructure.
Pelthos Therapeutics Earnings release: Q2 2026
Pelthos Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Pelthos Therapeutics Quarterly report: Q2 2026
Pelthos Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Pelthos Therapeutics Slides: Corporate presentation
Pelthos Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026
Pelthos Therapeutics Proxy statement: Proxy filing
Pelthos Therapeutics filed a proxy statement on August 7, 2026, providing details for shareholder voting and corporate governance matters.
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet pati...
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders v...
Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet pati...
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patie...
Pelthos Therapeutics price target raised to $66 from $62 at Oppenheimer
Oppenheimer analyst Jeff Jones raised the firm’s price target on Pelthos Therapeutics (PTHS) to $66 from $62 and keeps an Outperform rating on the shares after the company reported results…
Pelthos Therapeutics reports Q1 EPS ($3.58), consensus ($3.09)
Reports Q1 revenue $10.91M, consensus $10.44M. Scott Plesha, CEO of Pelthos, stated, “In the first quarter of 2026, we continued to build momentum for ZELSUVMI, driven by the expansion of…
Pelthos Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue growth and prescription gains for ZELSUVMI, supported by sales force expansion and a major PBM contract. Net loss narrowed, working capital improved, and launches for Xepi and Xeglyze are on track for 2027. Medicaid coverage for ZELSUVMI reached 99%.
Pelthos Therapeutics Earnings release: Q1 2026
Pelthos Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Pelthos Therapeutics Quarterly report: Q1 2026
Pelthos Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
ZELSUVMI ® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 uniq...
Pelthos Therapeutics Slides: Corporate presentation
Pelthos Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patie...
Pelthos Therapeutics Slides: Corporate presentation
Pelthos Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
Pelthos Therapeutics says John Gay to succeed Francis Knuettel II as CFO
Pelthos Therapeutics (PTHS) announced John Gay has been appointed CFO, effective April 10. Gay succeeds Francis Knuettel II, who served as Pelthos’ CFO since July 2025. Gay has served as…
Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight rating and $50 price target Pelthos is emerging as a commercial launch story, with early script trends indicating...